TG Therapeutics opened higher at $58.15, compared with its previous close of $58.08. In the last trading session, the stock traded between $58.00 and $61.76. It showed an upward intraday trend.
An investment of $100 made 5 years ago in TG Therapeutics is now worth
$ 195.52
giving a profit of
$ 95.52 (95.52%)
Note: Past profits do not guarantee future returns.
Rating from 5 Analysts
Today's Change
+$2.96 (+5.10%)
Day High
$61.76
Day Low
$58.00
Day Open
$58.15
Prev Close
$58.08
Volume
12,73,038
1W Return
14.86%
1M Return
8.70%
3M Return
14.12%
6M Return
81.77%
1Y Return
80.70%
Market Cap ($ Mn)
9,343
PE Ratio
19.61
PB Ratio
13.66
PEG Ratio
0.03
ROE
112.28%
ROCE
20.37%
EPS (TTM)
$0.05
1 Week
14.86%
1 Month
8.70%
3 Months
14.12%
6 Months
81.77%
9 Months
103.47%
TG Therapeutics shows 88% disability-free rate in 7-year BRIUMVI data
Seven-year ULTIMATE I and II data show 88.3% of BRIUMVI-treated patients remained free from confirmed disability progression. Annualized relapse rate was 0.018 at Year 7, with no apparent increase in adverse event rates over time. Early initiation led to 11.7% disability progression versus 17.4% in patients switching from teriflunomide. Subcutaneous BRIUMVI Phase 1 data supports quarterly dosing with greater than 60% bioavailability relative to IV.
9 days agoTG Therapeutics Q2 Results: Earnings Call Set for August 3, 2026
TG Therapeutics has scheduled a conference call for August 3, 2026, at 8:30 AM ET to present its second quarter 2026 financial results and business outlook for the remainder of 2026. Chairman and CEO Michael S. Weiss will host the call, which will be accessible via dial-in and live webcast on the company's website. A press release detailing the financial results will be issued prior to the call, and an audio replay will remain available for 30 days post-event.
3mo agoKuehn Law investigates TG Therapeutics for potential breaches
Kuehn Law, PLLC is investigating TG Therapeutics, Inc. officers and directors for potential fiduciary breaches and self-dealing. Long-term TGTX stockholders are encouraged to contact Sophia Anne Silayan for free consultations regarding potential damages and corporate governance reforms.
3mo agoHC Wainwright raises TG Therapeutics target to $77
HC Wainwright & Co. analyst Emily Bodnar maintained a Buy rating for TG Therapeutics and increased the price target to $77 from $70, reflecting a positive outlook for the NASDAQ-listed company.
3mo agoB of A Securities raises TG Therapeutics price target to $20
B of A Securities analyst Alec Stranahan maintained an Underperform rating on TG Therapeutics but raised the price target to $20 from $17, reflecting a revised valuation outlook.
3mo agoTG Therapeutics starts Phase 2 clinical study of BRIUMVI
TG Therapeutics, Inc. (NASDAQ: TGTX) initiated a Phase 2 clinical trial evaluating BRIUMVI (ublituximab-xiiy) in adults with treatment-resistant schizophrenia. The open-label, single-arm, multicenter study targets approximately 60 participants aged 18 to 60 who have not responded to standard antipsychotic treatments. The primary endpoint measures a 20% reduction in PANSS scores at Week 12, with CEO Michael S. Weiss highlighting the potential role of B-cell depletion in addressing immune dysfunction associated with the disorder.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $540.00 | +1.95% | $1,36,868.94M | 31.55 | |
| $61.07 | +2.12% | $1,31,639.87M | 14.39 | |
| $222.76 | +4.01% | $88,933.81M | - | |
| $818.77 | +0.68% | $82,808.76M | 19.64 | |
| $897.85 | +0.68% | $56,462.20M | 38.99 | |
| $371.56 | -0.48% | $40,792.43M | 65.60 | |
| $190.27 | +0.82% | $40,781.71M | - | |
| $56.49 | -1.40% | $35,253.15M | 26.24 | |
| $65.93 | +1.71% | $29,357.11M | 32.37 | |
| $37.52 | +1.10% | $27,101.56M | - | |
| $111.59 | +15.07% | $24,369.25M | - | |
| $116.80 | -0.06% | $23,675.13M | 15.85 |
An investment of $100 made 5 years ago in TG Therapeutics is now worth
$ 195.52
giving a profit of
$ 95.52 (95.52%)
Note: Past profits do not guarantee future returns.
